What is the incidence of human metapneumovirus (hMPV) infection in children and adults?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 5, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Human Metapneumovirus Incidence

Human metapneumovirus (hMPV) causes respiratory tract infections in 5-20% of children and adults during winter months, with approximately 5-10% of pediatric hospitalizations for acute respiratory tract infections attributable to hMPV. 1, 2

General Population Incidence

Pediatric Populations

  • Overall detection rates range from 5.6% to 12.7% annually in hospitalized children with acute respiratory tract infections, with year-to-year variation 3, 4
  • hMPV accounts for 5-10% of hospitalizations among pediatric patients with acute respiratory tract infections globally 2
  • Nearly universal infection occurs by age 5 years, with 78.2% of hMPV-positive children being younger than 3 years of age 4, 5
  • Primary infection typically occurs during early childhood, though reinfections are frequent throughout life 2

Adult Populations

  • Annual infection rates of 1-9% are documented in adults using RT-PCR and serology for diagnosis 5
  • hMPV causes 6-12% of exacerbations of chronic obstructive pulmonary disease 5
  • Reinfections occur throughout adult life, often presenting with mild upper respiratory symptoms or asymptomatic infection in young adults 5

High-Risk Immunocompromised Populations

Hematopoietic Stem Cell Transplant Recipients

  • Symptomatic hMPV infections occur in 2.5-9% of patients during the first 2 years after allogeneic HSCT 1
  • Asymptomatic and prolonged viral shedding is common in this population, complicating true incidence estimates 1, 6
  • Mortality ranges from 10-30% in HSCT patients who develop lower respiratory tract disease 7

Leukemia Patients

  • hMPV is frequently codetected with other pathogens including bacteria, fungi, and other respiratory viruses, obscuring the true attributable burden 1, 7
  • Progression to lower respiratory tract disease carries significant mortality risk in this population 1

Seasonal and Geographic Patterns

  • Peak activity occurs in late winter to early spring in temperate climates 3, 8, 4
  • In tropical regions, circulation peaks in late spring and summer 8
  • hMPV demonstrates a stable seasonal rhythm with alternating winter and spring activity, with strong peaks in late spring-summer months every second year 3
  • One hMPV subgroup (A1, A2a, A2b, B1, B2) predominates each year and is displaced by another subgroup every 1-3 years 3
  • Monthly average temperature negatively correlates with hMPV incidence, with peaks during colder months 4

Clinical Context for Incidence Interpretation

Important caveats when interpreting incidence data:

  • Detection methods significantly impact reported incidence rates, with RT-PCR being more sensitive than antigen testing or culture 8
  • Coinfection rates are substantial, particularly with RSV, making it difficult to determine hMPV's true attributable morbidity 1, 7
  • Asymptomatic shedding rates may be high in immunocompromised populations, leading to potential overestimation of clinically significant disease 1, 6
  • The 3-5 day incubation period and high rates of asymptomatic shedding facilitate nosocomial outbreaks, particularly in healthcare settings 6, 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Human metapneumovirus subgroup changes and seasonality during epidemics.

The Pediatric infectious disease journal, 2010

Research

Human metapneumovirus infection in adults.

The Pediatric infectious disease journal, 2008

Guideline

Human Metapneumovirus Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Human Metapneumovirus Clinical Manifestations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Human metapneumovirus.

Seminars in respiratory and critical care medicine, 2011

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.